{ "instance": { "bpmc-20220930x10q.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 275, "dts": { "calculationLink": { "local": [ "bpmc-20220930_cal.xml" ] }, "definitionLink": { "local": [ "bpmc-20220930_def.xml" ] }, "inline": { "local": [ "bpmc-20220930x10q.htm" ] }, "labelLink": { "local": [ "bpmc-20220930_lab.xml" ] }, "presentationLink": { "local": [ "bpmc-20220930_pre.xml" ] }, "schema": { "local": [ "bpmc-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 533, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 27, "http://www.blueprintmedicines.com/20220930": 7, "http://xbrl.sec.gov/dei/2022": 5, "total": 39 }, "keyCustom": 88, "keyStandard": 231, "memberCustom": 29, "memberStandard": 29, "nsprefix": "bpmc", "nsuri": "http://www.blueprintmedicines.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Financing Arrangements", "role": "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangements", "shortName": "Financing Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Marketable Securities", "role": "http://www.blueprintmedicines.com/role/DisclosureMarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Fair Value of Financial Instruments", "role": "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForCreditLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Product Revenue Reserves and Allowances", "role": "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowances", "shortName": "Product Revenue Reserves and Allowances", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForCreditLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Inventory", "role": "http://www.blueprintmedicines.com/role/DisclosureInventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestrictedAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Restricted Cash", "role": "http://www.blueprintmedicines.com/role/DisclosureRestrictedCash", "shortName": "Restricted Cash", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestrictedAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Accrued Expenses", "role": "http://www.blueprintmedicines.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Collaboration and License Agreements", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreements", "shortName": "Collaboration and License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Stock-based Compensation", "role": "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation", "shortName": "Stock-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Net Loss Per Share", "role": "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Income Taxes", "role": "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Leases", "role": "http://www.blueprintmedicines.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Commitments and Contingencies", "role": "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)", "role": "http://www.blueprintmedicines.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies", "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_bpmc_RoyaltyPharmaRoyaltyPurchaseAgreementMember_tOVpSRDh1EGy-0NzpqqYHA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Financing Arrangements (Tables)", "role": "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables", "shortName": "Financing Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_bpmc_RoyaltyPharmaRoyaltyPurchaseAgreementMember_tOVpSRDh1EGy-0NzpqqYHA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Marketable Securities (Tables)", "role": "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:AllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_LYuMEDxo8UyKqO4TqnvXEA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Product Revenue Reserves and Allowances (Tables)", "role": "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesTables", "shortName": "Product Revenue Reserves and Allowances (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_LYuMEDxo8UyKqO4TqnvXEA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "bpmc:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Inventory (Tables)", "role": "http://www.blueprintmedicines.com/role/DisclosureInventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "bpmc:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_jAIKO7FXhUGlem12K4q9ow", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_jAIKO7FXhUGlem12K4q9ow", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "bpmc:ScheduleOfManufacturingServicesRelatedToAgreementActivitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Collaboration and License Agreements (Tables)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "shortName": "Collaboration and License Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "bpmc:ScheduleOfManufacturingServicesRelatedToAgreementActivitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Stock-based Compensation (Tables)", "role": "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Leases (Tables)", "role": "http://www.blueprintmedicines.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentsAndCash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Nature of Business (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureNatureOfBusinessDetails", "shortName": "Nature of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentsAndCash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_bpmc_SixthStreetPartnersFinancingArrangementsMember_LfDpEG6M6k2_kHfva6_rxA", "decimals": "INF", "first": true, "lang": null, "name": "bpmc:DebtInstrumentTransactionsNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_Transaction_iek4REDtE0aCiL_uy_x_kQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Financing Arrangements - General Information (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "shortName": "Financing Arrangements - General Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_7_31_2022_us-gaap_DebtInstrumentAxis_bpmc_SixthStreetPartnersFinancingArrangementsMember_LfDpEG6M6k2_kHfva6_rxA", "decimals": "INF", "first": true, "lang": null, "name": "bpmc:DebtInstrumentTransactionsNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_Transaction_iek4REDtE0aCiL_uy_x_kQ", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_7_31_2022_srt_CounterpartyNameAxis_bpmc_SixthStreetPartnersMember_EiRATAqnA0C--PJBV2H0rA", "decimals": "INF", "first": true, "lang": null, "name": "bpmc:PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesPercentageRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_GF1v_K9MYkGnbAnqE5J2JQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Financing Arrangements - Royalty and Sales Information (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails", "shortName": "Financing Arrangements - Royalty and Sales Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_7_31_2022_srt_CounterpartyNameAxis_bpmc_SixthStreetPartnersMember_EiRATAqnA0C--PJBV2H0rA", "decimals": "INF", "first": true, "lang": null, "name": "bpmc:PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesPercentageRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_GF1v_K9MYkGnbAnqE5J2JQ", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_DebtInstrumentAxis_bpmc_RoyaltyPharmaRoyaltyPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_bpmc_SaleOfFutureRoyaltiesAndRevenuesMember_U3aUflWzRUS-kduPVT1NNg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - Financing Arrangements - Long-term Debt (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "shortName": "Financing Arrangements - Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_LongtermDebtTypeAxis_bpmc_SaleOfFutureRoyaltiesAndRevenuesMember_cBzoCvhxwkKhV6TdecHkXQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40304 - Disclosure - Financing Arrangements - Roll Forward (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "shortName": "Financing Arrangements - Roll Forward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_bpmc_RoyaltyPharmaRoyaltyPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_bpmc_SaleOfFutureRoyaltiesAndRevenuesMember_LVcwlZTajkC3y0yZfROFdA", "decimals": "-3", "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_6_30_2022_zPLJxCmT1EW9ChGIYsgg7A", "decimals": "-5", "first": true, "lang": null, "name": "bpmc:RoyaltyPurchaseAgreementMilestonePaymentsAchievementOfSpecifiedNetSalesMilestonesMaximum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40305 - Disclosure - Financing Arrangements - Additional Information (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsAdditionalInformationDetails", "shortName": "Financing Arrangements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_6_30_2022_zPLJxCmT1EW9ChGIYsgg7A", "decimals": "-5", "first": true, "lang": null, "name": "bpmc:RoyaltyPurchaseAgreementMilestonePaymentsAchievementOfSpecifiedNetSalesMilestonesMaximum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Marketable Securities - Tabular Disclosure (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails", "shortName": "Marketable Securities - Tabular Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_security_0zMPvDOt7U-ClBA-xmRMFg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Marketable Securities - Unrealized Loss Position (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesUnrealizedLossPositionDetails", "shortName": "Marketable Securities - Unrealized Loss Position (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_security_0zMPvDOt7U-ClBA-xmRMFg", "xsiNil": "false" } }, "R42": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - Marketable Securities - Impairment (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesImpairmentDetails", "shortName": "Marketable Securities - Impairment (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "INF", "first": true, "lang": null, "name": "bpmc:DebtSecuritiesAvailableForSaleNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_security_0zMPvDOt7U-ClBA-xmRMFg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40404 - Disclosure - Marketable Securities - Remaining Maturities (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesRemainingMaturitiesDetails", "shortName": "Marketable Securities - Remaining Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "INF", "first": true, "lang": null, "name": "bpmc:DebtSecuritiesAvailableForSaleNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_security_0zMPvDOt7U-ClBA-xmRMFg", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40405 - Disclosure - Marketable Securities - Proceeds from Maturities (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesProceedsFromMaturitiesDetails", "shortName": "Marketable Securities - Proceeds from Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R45": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "40406 - Disclosure - Marketable Securities - Realized Gains (Losses) (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesRealizedGainsLossesDetails", "shortName": "Marketable Securities - Realized Gains (Losses) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Fair Value of Financial Instruments (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_y56zmbgB10eX3_Djwa2cQg", "decimals": "-3", "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Product Revenue Reserves and Allowances - Product Revenue (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueDetails", "shortName": "Product Revenue Reserves and Allowances - Product Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:AllowanceForCreditLossesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_ProductOrServiceAxis_bpmc_AyvakitAndAyvakytMember_3LYjweMoYEivD7aOK-PuSA", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_reyvNXmMck2IBVkKdbt29Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Product Revenue Reserves and Allowances - Product Revenue Allowance and Reserve (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReserveDetails", "shortName": "Product Revenue Reserves and Allowances - Product Revenue Allowance and Reserve (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerAssetCreditLossExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40603 - Disclosure - Product Revenue Reserves and Allowances - Revenue-related Reserves (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesRevenueRelatedReservesDetails", "shortName": "Product Revenue Reserves and Allowances - Revenue-related Reserves (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember_6VNSjqqlnke21qP-kn5iiw", "decimals": "-3", "lang": null, "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ot7etruYjEyht2PmfNXLDA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vmsluYVJb0CZWQcTuQQmTA", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "bpmc:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "bpmc:InventoryCurrentAndNoncurrentRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Inventory - Capitalized (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureInventoryCapitalizedDetails", "shortName": "Inventory - Capitalized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "bpmc:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "bpmc:InventoryCurrentAndNoncurrentRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - Inventory - Balance Sheet Classification (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureInventoryBalanceSheetClassificationDetails", "shortName": "Inventory - Balance Sheet Classification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "bpmc:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "lang": null, "name": "us-gaap:InventoryNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_-WH5yGzdak2o-336EImJLQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryWriteDown", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40703 - Disclosure - Inventory - Write-down (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureInventoryWriteDownDetails", "shortName": "Inventory - Write-down (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2021_To_9_30_2021_-WH5yGzdak2o-336EImJLQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryWriteDown", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RestrictedAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Restricted Cash (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureRestrictedCashDetails", "shortName": "Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RestrictedAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "bpmc:ExternalResearchDevelopmentAndCommercialContractCostsCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Accrued Expenses (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_reyvNXmMck2IBVkKdbt29Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Collaboration and License Agreements - General Information (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "shortName": "Collaboration and License Agreements - General Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_IdrxIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_Xr2rVyanxkCfqkeaY6JAQw", "decimals": null, "lang": "en-US", "name": "bpmc:CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_11_8_2021_To_12_31_2021_srt_CounterpartyNameAxis_bpmc_ZaiLabShanghaiCoLtdMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_gFsaZ29H_06zFsGLrTIX5A", "decimals": "-5", "first": true, "lang": null, "name": "bpmc:CollaborativeArrangementTransactionPrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Collaboration and License Agreements - Transaction Price (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails", "shortName": "Collaboration and License Agreements - Transaction Price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_11_8_2021_To_12_31_2021_srt_CounterpartyNameAxis_bpmc_ZaiLabShanghaiCoLtdMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_gFsaZ29H_06zFsGLrTIX5A", "decimals": "-5", "first": true, "lang": null, "name": "bpmc:CollaborativeArrangementTransactionPrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Collaboration and License Agreements - Equity Investment (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "shortName": "Collaboration and License Agreements - Equity Investment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_8_1_2022_srt_CounterpartyNameAxis_bpmc_IdrxIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_fMPenzkpJkW_Blga4OO9wg", "decimals": "-5", "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_13_2020_To_7_13_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O8D4tRIobUqqV3_f2ygYKg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41004 - Disclosure - Collaboration and License Agreements - Sale of Stock (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails", "shortName": "Collaboration and License Agreements - Sale of Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_13_2020_To_7_13_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_O8D4tRIobUqqV3_f2ygYKg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "bpmc:ScheduleOfManufacturingServicesRelatedToAgreementActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_CStoneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_rgnxbu6VxEaaLkXW510yjQ", "decimals": "-3", "first": true, "lang": null, "name": "bpmc:CollaborativeArrangementManufacturingAndResearchAndDevelopmentServicesRelatedToGlobalDevelopmentActivitiesNetOfCostSharingPayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41005 - Disclosure - Collaboration and License Agreements - Manufacturing and Research and Development Services (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsManufacturingAndResearchAndDevelopmentServicesDetails", "shortName": "Collaboration and License Agreements - Manufacturing and Research and Development Services (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "bpmc:ScheduleOfManufacturingServicesRelatedToAgreementActivitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_CStoneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_rgnxbu6VxEaaLkXW510yjQ", "decimals": "-3", "first": true, "lang": null, "name": "bpmc:CollaborativeArrangementManufacturingAndResearchAndDevelopmentServicesRelatedToGlobalDevelopmentActivitiesNetOfCostSharingPayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41006 - Disclosure - Collaboration and License Agreements - Revenue Recognized (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "shortName": "Collaboration and License Agreements - Revenue Recognized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_CounterpartyNameAxis_bpmc_ZaiLabShanghaiCoLtdMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_U70kyTmsbECmhNMMX0yv8w", "decimals": "-5", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "bpmc:CollaborationProfitLossSharing", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41007 - Disclosure - Collaboration and License Agreements - Collaboration Loss Sharing (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsCollaborationLossSharingDetails", "shortName": "Collaboration and License Agreements - Collaboration Loss Sharing (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "bpmc:ScheduleOfCollaborationLossSharingTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_RocheCollaborationPralsetnibAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_gEyhITj6uk2kxWRN88F7nA", "decimals": "-3", "lang": null, "name": "bpmc:CollaborationProfitLossSharing", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_ZaiLabShanghaiCoLtdMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_VD5W1Rinz02eldMqNBCsaQ", "decimals": "-5", "first": true, "lang": null, "name": "bpmc:CollaborativeArrangementGlobalDevelopmentActivitiesReductionInResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41008 - Disclosure - Collaboration and License Agreements - Reduction in Expenses (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails", "shortName": "Collaboration and License Agreements - Reduction in Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_ZaiLabShanghaiCoLtdMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_VD5W1Rinz02eldMqNBCsaQ", "decimals": "-5", "first": true, "lang": null, "name": "bpmc:CollaborativeArrangementGlobalDevelopmentActivitiesReductionInResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_RocheCollaborationAndLicenseImmunotherapyAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tLtHqg6L5kezurdhNcrRcQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41009 - Disclosure - Collaboration and License Agreements - Change in Contract with Customer, Liability (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails", "shortName": "Collaboration and License Agreements - Change in Contract with Customer, Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_RocheCollaborationAndLicenseImmunotherapyAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_tLtHqg6L5kezurdhNcrRcQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41010 - Disclosure - Collaboration and License Agreements - Contract Assets and Liabilities (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "shortName": "Collaboration and License Agreements - Contract Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_srt_CounterpartyNameAxis_bpmc_RocheCollaborationPralsetnibAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_p48zqlA5F0GTTwStqDX8cg", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_IdrxIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_Xr2rVyanxkCfqkeaY6JAQw", "decimals": "INF", "first": true, "lang": null, "name": "bpmc:CollaborativeArrangementMaterialPromisesNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_wN6di1q4T0Kjvh2rThRd0Q", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41011 - Disclosure - Collaboration and License Agreements - Performance Obligations (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "shortName": "Collaboration and License Agreements - Performance Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_IdrxIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_Xr2rVyanxkCfqkeaY6JAQw", "decimals": "INF", "first": true, "lang": null, "name": "bpmc:CollaborativeArrangementMaterialPromisesNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_wN6di1q4T0Kjvh2rThRd0Q", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_4_8_2015_us-gaap_PlanNameAxis_bpmc_StockOptionAndIncentivePlan2015Member_U1CiSvUZpUy19CxeiCghFw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Stock-based Compensation - 2015 Stock Option and Incentive Plan (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2015StockOptionAndIncentivePlanDetails", "shortName": "Stock-based Compensation - 2015 Stock Option and Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_4_8_2015_us-gaap_PlanNameAxis_bpmc_StockOptionAndIncentivePlan2015Member_U1CiSvUZpUy19CxeiCghFw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_3_31_2020_us-gaap_PlanNameAxis_bpmc_InducementPlan2020Member_IM9WM_NFG0u0Nk3jhxJy7A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Stock-based Compensation - 2020 Inducement Plan (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2020InducementPlanDetails", "shortName": "Stock-based Compensation - 2020 Inducement Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_3_31_2020_us-gaap_PlanNameAxis_bpmc_InducementPlan2020Member_IM9WM_NFG0u0Nk3jhxJy7A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_reyvNXmMck2IBVkKdbt29Q", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41103 - Disclosure - Stock-based Compensation - Stock Options - Activity (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails", "shortName": "Stock-based Compensation - Stock Options - Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_reyvNXmMck2IBVkKdbt29Q", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41104 - Disclosure - Stock-based Compensation - Unrecognized Compensation Costs (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationUnrecognizedCompensationCostsDetails", "shortName": "Stock-based Compensation - Unrecognized Compensation Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00405 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical)", "role": "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2021_dUrJw5qd1U6ygVAKAaWRGw", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dxkAoGGjv0eIgCKXnNMutA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41105 - Disclosure - Stock-based Compensation - Restricted Stock Units - Activity (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails", "shortName": "Stock-based Compensation - Restricted Stock Units - Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_dxkAoGGjv0eIgCKXnNMutA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_5_31_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_6u35kXlUs0mZu2Nfv0W7Sw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41106 - Disclosure - Stock-based Compensation - Employee Stock Purchase Plan (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "shortName": "Stock-based Compensation - Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_5_31_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_6u35kXlUs0mZu2Nfv0W7Sw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41107 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense - General Information (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseGeneralInformationDetails", "shortName": "Stock-based Compensation - Stock-based Compensation Expense - General Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41108 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense - By Type (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails", "shortName": "Stock-based Compensation - Stock-based Compensation Expense - By Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41109 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense - By Classification (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByClassificationDetails", "shortName": "Stock-based Compensation - Stock-based Compensation Expense - By Classification (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kv58RsZZF06w29slECxZ-A", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Net Loss Per Share (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareDetails", "shortName": "Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0zWKGMquhEC0IklY5Z6enQ", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_LongtermDebtTypeAxis_bpmc_SaleOfFutureRoyaltiesAndRevenuesMember_cBzoCvhxwkKhV6TdecHkXQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Income Taxes - Financing Arrangements (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails", "shortName": "Income Taxes - Financing Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R77": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - Income Taxes - Equity Investment (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails", "shortName": "Income Taxes - Equity Investment (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R78": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41303 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails", "shortName": "Income Taxes - Income Tax Expense (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R79": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Leases - Components of Lease Expense (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails", "shortName": "Leases - Components of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_71zfIPXo6ECS-uXpf0EcRQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Nature of Business", "role": "http://www.blueprintmedicines.com/role/DisclosureNatureOfBusiness", "shortName": "Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41402 - Disclosure - Leases - Cash Flow Information (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureLeasesCashFlowInformationDetails", "shortName": "Leases - Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41403 - Disclosure - Leases - Weighted Average Remaining Lease-term and Weighted Average Discount Rate (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails", "shortName": "Leases - Weighted Average Remaining Lease-term and Weighted Average Discount Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_tK9aSZFE5UC9cr-nUkQnPg", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_ManufacturingAgreementOctober2020Member_E5wVtc-vZU2oepXIvioqIA", "decimals": "-5", "first": true, "lang": null, "name": "bpmc:UnrecordedUnconditionalPurchaseObligationPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails", "shortName": "Commitments and Contingencies - Purchase Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_bpmc_ManufacturingAgreementOctober2020Member_E5wVtc-vZU2oepXIvioqIA", "decimals": "-5", "first": true, "lang": null, "name": "bpmc:UnrecordedUnconditionalPurchaseObligationPeriodIncreaseDecrease", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_v_Eiy4Jwmkaad2RpKUmLKg", "xsiNil": "false" } }, "R83": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "41502 - Disclosure - Commitments and Contingencies - Indemnification Agreements (Details)", "role": "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesIndemnificationAgreementsDetails", "shortName": "Commitments and Contingencies - Indemnification Agreements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of Significant Accounting Policies and Recent Accounting Pronouncements", "role": "http://www.blueprintmedicines.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements", "shortName": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bpmc-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_3wvHdTcJ2UGrNJdIJrAjHw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 61, "tag": { "bpmc_AccruedContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued accumulated credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Accrued Contract With Customer Asset Accumulated Allowance For Credit Loss", "terseLabel": "Revenue-related reserves" } } }, "localname": "AccruedContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_AnnualCumulativeIncreasePercentageOfNumberOfShareOfCommonStockIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the annual cumulative increase for common stock issuance, as a percentage of the number of shares of common stock issued and outstanding.", "label": "Annual Cumulative Increase Percentage of Number of Share of Common Stock Issued and Outstanding", "terseLabel": "Annual increase for common stock for issuance (as a percent)" } } }, "localname": "AnnualCumulativeIncreasePercentageOfNumberOfShareOfCommonStockIssuedAndOutstanding", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "xbrltype": "percentItemType" }, "bpmc_AyvakitAndAyvakytMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AYVAKIT and AYVAKYT [Member]", "label": "AYVAKIT and AYVAKYT", "terseLabel": "AYVAKIT and AYVAKYT" } } }, "localname": "AyvakitAndAyvakytMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueDetails" ], "xbrltype": "domainItemType" }, "bpmc_CStoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "C Stone [Member]", "label": "C Stone" } } }, "localname": "CStoneMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsManufacturingAndResearchAndDevelopmentServicesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "bpmc_ClementiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clementia [Member]", "label": "Clementia" } } }, "localname": "ClementiaMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "bpmc_CollaborationAndLicenseExcludingRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration and License, Excluding Related Party [Member]", "label": "Collaboration and License, Excluding Related Party [Member]", "terseLabel": "Collaboration and license revenue" } } }, "localname": "CollaborationAndLicenseExcludingRelatedPartyMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "bpmc_CollaborationAndLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration and License [Member]", "label": "Collaboration and License [Member]", "terseLabel": "Collaboration and license revenue" } } }, "localname": "CollaborationAndLicenseMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "bpmc_CollaborationAndLicenseRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration and License, Related Party [Member]", "label": "Collaboration and License, Related Party [Member]" } } }, "localname": "CollaborationAndLicenseRelatedPartyMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "bpmc_CollaborationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration [Member]", "label": "Collaboration revenue" } } }, "localname": "CollaborationMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "domainItemType" }, "bpmc_CollaborationProfitLossSharing": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaboration Profit (Loss) Sharing", "label": "Collaboration Profit (Loss) Sharing", "terseLabel": "Collaboration loss sharing" } } }, "localname": "CollaborationProfitLossSharing", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsCollaborationLossSharingDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementClinicalTrialsSharedDevelopmentCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Clinical Trials, Shared Development Cost", "label": "Collaborative Arrangement, Clinical Trials, Shared Development Cost", "terseLabel": "Collaborative arrangement, clinical trials, shared development cost" } } }, "localname": "CollaborativeArrangementClinicalTrialsSharedDevelopmentCost", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementCollaborationProgramsLicensedProductsCommercializationRightsCounterpartyExercisesOptionCounterpartyReceivesWorldwideExclusivityNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Collaboration Programs, Licensed Products, Commercialization Rights, Counterparty Exercises Option, Counterparty Receives Worldwide Exclusivity, Number", "label": "Collaborative Arrangement, Collaboration Programs, Licensed Products, Commercialization Rights, Counterparty Exercises Option, Counterparty Receives Worldwide Exclusivity, Number", "terseLabel": "Collaborative arrangement, collaboration programs, licensed products, commercialization rights, counterparty exercises option, counterparty receives worldwide exclusivity, number" } } }, "localname": "CollaborativeArrangementCollaborationProgramsLicensedProductsCommercializationRightsCounterpartyExercisesOptionCounterpartyReceivesWorldwideExclusivityNumber", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "integerItemType" }, "bpmc_CollaborativeArrangementCollaborationProgramsLicensedProductsCommercializationRightsCounterpartyExercisesOptionEntityRetainsDomesticAndCounterpartyReceivesInternationalNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Collaboration Programs, Licensed Products, Commercialization Rights, Counterparty Exercises Option, Entity Retains Domestic and Counterparty Receives International, Number", "label": "Collaborative Arrangement, Collaboration Programs, Licensed Products, Commercialization Rights, Counterparty Exercises Option, Entity Retains Domestic and Counterparty Receives International, Number", "terseLabel": "Collaborative arrangement, collaboration programs, licensed products, commercialization rights, counterparty exercises option, entity retains domestic and counterparty receives international, number" } } }, "localname": "CollaborativeArrangementCollaborationProgramsLicensedProductsCommercializationRightsCounterpartyExercisesOptionEntityRetainsDomesticAndCounterpartyReceivesInternationalNumber", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "integerItemType" }, "bpmc_CollaborativeArrangementCollaborationProgramsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Collaboration Programs, Number", "label": "Collaborative Arrangement, Collaboration Programs, Number", "terseLabel": "Collaborative arrangement, collaboration programs, number" } } }, "localname": "CollaborativeArrangementCollaborationProgramsNumber", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "integerItemType" }, "bpmc_CollaborativeArrangementCollaborationProgramsWithExclusiveCommercializationRightsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Collaboration Programs with Exclusive Commercialization Rights, Number", "label": "Collaborative Arrangement, Collaboration Programs with Exclusive Commercialization Rights, Number", "terseLabel": "Collaborative arrangement, collaboration programs with exclusive commercialization rights, number" } } }, "localname": "CollaborativeArrangementCollaborationProgramsWithExclusiveCommercializationRightsNumber", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "integerItemType" }, "bpmc_CollaborativeArrangementCommercializationReductionInSellingGeneralAndAdministrativeExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Commercialization, Reduction in Selling, General and Administrative Expenses", "label": "Collaborative Arrangement, Commercialization, Reduction in Selling, General and Administrative Expenses", "terseLabel": "Collaborative arrangement, commercialization, reduction in selling, general and administrative expenses" } } }, "localname": "CollaborativeArrangementCommercializationReductionInSellingGeneralAndAdministrativeExpenses", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement Disclosure [Abstract]", "label": "Collaborative Arrangement Disclosure [Abstract]" } } }, "localname": "CollaborativeArrangementDisclosureAbstract", "nsuri": "http://www.blueprintmedicines.com/20220930", "xbrltype": "stringItemType" }, "bpmc_CollaborativeArrangementGlobalDevelopmentActivitiesReductionInResearchAndDevelopmentExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Global Development Activities, Reduction in Research and Development Expenses", "label": "Collaborative Arrangement, Global Development Activities, Reduction in Research and Development Expenses", "terseLabel": "Collaborative arrangement, global development activities, reduction in research and development expenses" } } }, "localname": "CollaborativeArrangementGlobalDevelopmentActivitiesReductionInResearchAndDevelopmentExpenses", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementInventoryPurchasedByCounterparty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Inventory Purchased by Counterparty", "label": "Collaborative Arrangement, Inventory Purchased by Counterparty", "terseLabel": "Collaborative arrangement, inventory purchased by counterparty" } } }, "localname": "CollaborativeArrangementInventoryPurchasedByCounterparty", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementLicenseOptionRightsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, License Option Rights, Number", "label": "Collaborative Arrangement, License Option Rights, Number", "terseLabel": "Collaborative arrangement, license option rights, number" } } }, "localname": "CollaborativeArrangementLicenseOptionRightsNumber", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "integerItemType" }, "bpmc_CollaborativeArrangementLicensedProductTermFromFirstCommercialSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Licensed Product Term from First Commercial Sale", "label": "Collaborative Arrangement, Licensed Product Term from First Commercial Sale", "terseLabel": "Collaborative arrangement, licensed product term from first commercial sale" } } }, "localname": "CollaborativeArrangementLicensedProductTermFromFirstCommercialSale", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "durationItemType" }, "bpmc_CollaborativeArrangementManufacturingAndResearchAndDevelopmentServicesRelatedToGlobalDevelopmentActivitiesNetOfCostSharingPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Manufacturing and Research and Development Services Related to Global Development Activities, Net of Cost Sharing Payments", "label": "Collaborative Arrangement, Manufacturing and Research and Development Services Related to Global Development Activities, Net of Cost Sharing Payments", "terseLabel": "Manufacturing and research and development services related to global development activities, net of expenses payable" } } }, "localname": "CollaborativeArrangementManufacturingAndResearchAndDevelopmentServicesRelatedToGlobalDevelopmentActivitiesNetOfCostSharingPayments", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsManufacturingAndResearchAndDevelopmentServicesDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementMaterialComponentsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Material Components, Number", "label": "Collaborative Arrangement, Material Components, Number", "terseLabel": "Collaborative arrangement, material components, number" } } }, "localname": "CollaborativeArrangementMaterialComponentsNumber", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails" ], "xbrltype": "integerItemType" }, "bpmc_CollaborativeArrangementMaterialPromisesCombinedIntoDistinctPerformanceObligationNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Material Promises, Combined into Distinct Performance Obligation, Number", "label": "Collaborative Arrangement, Material Promises, Combined into Distinct Performance Obligation, Number", "terseLabel": "Collaborative arrangement, material promises, combined into distinct performance obligation, number" } } }, "localname": "CollaborativeArrangementMaterialPromisesCombinedIntoDistinctPerformanceObligationNumber", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails" ], "xbrltype": "integerItemType" }, "bpmc_CollaborativeArrangementMaterialPromisesManufacturingActivitiesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Material Promises, Manufacturing Activities, Term", "label": "Collaborative Arrangement, Material Promises, Manufacturing Activities, Term", "terseLabel": "Collaborative arrangement, material promises, manufacturing activities, term" } } }, "localname": "CollaborativeArrangementMaterialPromisesManufacturingActivitiesTerm", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails" ], "xbrltype": "durationItemType" }, "bpmc_CollaborativeArrangementMaterialPromisesNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Material Promises, Number", "label": "Collaborative Arrangement, Material Promises, Number", "terseLabel": "Collaborative arrangement, material promises, number" } } }, "localname": "CollaborativeArrangementMaterialPromisesNumber", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails" ], "xbrltype": "integerItemType" }, "bpmc_CollaborativeArrangementMilestonesAchieved": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Milestones, Achieved", "label": "Collaborative Arrangement, Milestones, Achieved", "terseLabel": "Collaborative arrangement, milestones, achieved" } } }, "localname": "CollaborativeArrangementMilestonesAchieved", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementMilestonesCashPaymentsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Milestones, Cash Payments Received", "label": "Collaborative Arrangement, Milestones, Cash Payments Received", "terseLabel": "Collaborative arrangement, milestones, cash payments received" } } }, "localname": "CollaborativeArrangementMilestonesCashPaymentsReceived", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementMilestonesCashPaymentsReceivedAggregate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Milestones, Cash Payments Received, Aggregate", "label": "Collaborative Arrangement, Milestones, Cash Payments Received, Aggregate", "terseLabel": "Collaborative arrangement, milestones, cash payments received, aggregate" } } }, "localname": "CollaborativeArrangementMilestonesCashPaymentsReceivedAggregate", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementMilestonesContingentPaymentsEligibleToReceive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Milestones, Contingent Payments Eligible to Receive", "label": "Collaborative Arrangement, Milestones, Contingent Payments Eligible to Receive", "terseLabel": "Collaborative arrangement, milestones, contingent payments eligible to receive" } } }, "localname": "CollaborativeArrangementMilestonesContingentPaymentsEligibleToReceive", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementMilestonesPotentialContingentPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Milestones, Potential Contingent Payments", "label": "Collaborative Arrangement, Milestones, Potential Contingent Payments", "terseLabel": "Collaborative arrangement, milestones, potential contingent payments" } } }, "localname": "CollaborativeArrangementMilestonesPotentialContingentPayments", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementMilestonesResearchMilestonesAchieved": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Milestones, Research Milestones, Achieved", "label": "Collaborative Arrangement, Milestones, Research Milestones, Achieved", "terseLabel": "Collaborative arrangement, milestones, research milestones, achieved" } } }, "localname": "CollaborativeArrangementMilestonesResearchMilestonesAchieved", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementMilestonesSpecifiedRegulatoryAndCommercializationMilestonesAchieved": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Milestones, Specified Regulatory and Commercialization Milestones, Achieved", "label": "Collaborative Arrangement, Milestones, Specified Regulatory and Commercialization Milestones, Achieved", "terseLabel": "Collaborative arrangement, milestones, specified regulatory and commercialization milestones, achieved" } } }, "localname": "CollaborativeArrangementMilestonesSpecifiedRegulatoryAndCommercializationMilestonesAchieved", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementOptionFeesAndMilestonesContingentPaymentsEligibleToReceive": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Option Fees and Milestones, Contingent Payments Eligible to Receive", "label": "Collaborative Arrangement, Option Fees and Milestones, Contingent Payments Eligible to Receive", "terseLabel": "Collaborative arrangement, option fees and milestones, contingent payments eligible to receive" } } }, "localname": "CollaborativeArrangementOptionFeesAndMilestonesContingentPaymentsEligibleToReceive", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementPercentageOfGlobalDevelopmentCostsSharedCounterparty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Percentage of Global Development Costs Shared, Counterparty", "label": "Collaborative Arrangement, Percentage of Global Development Costs Shared, Counterparty", "terseLabel": "Collaborative arrangement, percentage of global development costs shared, counterparty (as a percent)" } } }, "localname": "CollaborativeArrangementPercentageOfGlobalDevelopmentCostsSharedCounterparty", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "bpmc_CollaborativeArrangementPercentageOfGlobalDevelopmentCostsSharedEntity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Percentage of Global Development Costs Shared, Entity", "label": "Collaborative Arrangement, Percentage of Global Development Costs Shared, Entity", "terseLabel": "Collaborative arrangement, percentage of global development costs shared, entity (as a percent)" } } }, "localname": "CollaborativeArrangementPercentageOfGlobalDevelopmentCostsSharedEntity", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "bpmc_CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Termination, Counterparty Written Notice Period", "label": "Collaborative Arrangement, Termination, Counterparty Written Notice Period", "terseLabel": "Collaborative arrangement, termination, counterparty written notice period" } } }, "localname": "CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriod", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "durationItemType" }, "bpmc_CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriodAfterOptionExerciseIfLicensedProductsHaveBeenCommerciallySold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Termination, Counterparty Written Notice Period, After Option Exercise, If Licensed Products Have Been Commercially Sold", "label": "Collaborative Arrangement, Termination, Counterparty Written Notice Period, After Option Exercise, If Licensed Products Have Been Commercially Sold", "terseLabel": "Collaborative arrangement, termination, counterparty written notice period, after option exercise, if licensed products have been commercially sold" } } }, "localname": "CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriodAfterOptionExerciseIfLicensedProductsHaveBeenCommerciallySold", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "durationItemType" }, "bpmc_CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriodAfterOptionExerciseIfLicensedProductsHaveNotBeenCommerciallySold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Termination, Counterparty Written Notice Period, After Option Exercise, If Licensed Products Have Not Been Commercially Sold", "label": "Collaborative Arrangement, Termination, Counterparty Written Notice Period, After Option Exercise, If Licensed Products Have Not Been Commercially Sold", "terseLabel": "Collaborative arrangement, termination, counterparty written notice period, after option exercise, if licensed products have not been commercially sold" } } }, "localname": "CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriodAfterOptionExerciseIfLicensedProductsHaveNotBeenCommerciallySold", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "durationItemType" }, "bpmc_CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriodPeriodFromEffectiveDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Termination, Counterparty Written Notice Period, Period from Effective Date", "label": "Collaborative Arrangement, Termination, Counterparty Written Notice Period, Period from Effective Date", "terseLabel": "Collaborative arrangement, termination, counterparty written notice period, period from effective date" } } }, "localname": "CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriodPeriodFromEffectiveDate", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "durationItemType" }, "bpmc_CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriodPeriodFromEffectiveDateGivenAfterFirstCommercialSaleOfLicensedProductInCounterpartyTerritory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Termination, Counterparty Written Notice Period, Period from Effective Date, Given after First Commercial Sale of Licensed Product in Counterparty Territory", "label": "Collaborative Arrangement, Termination, Counterparty Written Notice Period, Period from Effective Date, Given after First Commercial Sale of Licensed Product in Counterparty Territory", "terseLabel": "Collaborative arrangement, termination, counterparty written notice period, period from effective date, given after first commercial sale of licensed product in counterparty territory" } } }, "localname": "CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriodPeriodFromEffectiveDateGivenAfterFirstCommercialSaleOfLicensedProductInCounterpartyTerritory", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "durationItemType" }, "bpmc_CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriodPeriodFromEffectiveDateGivenPriorToFirstCommercialSaleOfLicensedProductInCounterpartyTerritory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Termination, Counterparty Written Notice Period, Period from Effective Date, Given Prior to First Commercial Sale of Licensed Product in Counterparty Territory", "label": "Collaborative Arrangement, Termination, Counterparty Written Notice Period, Period from Effective Date, Given Prior to First Commercial Sale of Licensed Product in Counterparty Territory", "terseLabel": "Collaborative arrangement, termination, counterparty written notice period, period from effective date, given prior to first commercial sale of licensed product in counterparty territory" } } }, "localname": "CollaborativeArrangementTerminationCounterpartyWrittenNoticePeriodPeriodFromEffectiveDateGivenPriorToFirstCommercialSaleOfLicensedProductInCounterpartyTerritory", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "durationItemType" }, "bpmc_CollaborativeArrangementTransactionPrice": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Transaction Price", "label": "Collaborative Arrangement, Transaction Price", "totalLabel": "Collaborative arrangement, transaction price" } } }, "localname": "CollaborativeArrangementTransactionPrice", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementTransactionPriceMilestonePaymentsReceivable": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails": { "order": 3.0, "parentTag": "bpmc_CollaborativeArrangementTransactionPrice", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Transaction Price, Milestone Payments Receivable", "label": "Collaborative Arrangement, Transaction Price, Milestone Payments Receivable", "terseLabel": "Collaborative arrangement, transaction price, milestone payments receivable" } } }, "localname": "CollaborativeArrangementTransactionPriceMilestonePaymentsReceivable", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementTransactionPricePaymentCommitmentReduction": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Transaction Price, Payment Commitment Reduction", "label": "Collaborative Arrangement, Transaction Price, Payment Commitment Reduction", "terseLabel": "Collaborative arrangement, transaction price, payment commitment reduction" } } }, "localname": "CollaborativeArrangementTransactionPricePaymentCommitmentReduction", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementTransactionPriceReduction": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Transaction Price, Reduction", "label": "Collaborative Arrangement, Transaction Price, Reduction", "terseLabel": "Collaborative arrangement, transaction price, reduction" } } }, "localname": "CollaborativeArrangementTransactionPriceReduction", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementTransactionPriceResearchMilestoneAchievedCashConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Transaction Price, Research Milestone Achieved, Cash Consideration", "label": "Collaborative Arrangement, Transaction Price, Research Milestone Achieved, Cash Consideration", "terseLabel": "Collaborative arrangement, transaction price, research milestone achieved, cash consideration" } } }, "localname": "CollaborativeArrangementTransactionPriceResearchMilestoneAchievedCashConsideration", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementTransactionPriceStockIssuedPremiumOnSaleOfStockToCounterparty": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails": { "order": 2.0, "parentTag": "bpmc_CollaborativeArrangementTransactionPrice", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Transaction Price, Stock Issued, Premium on Sale of Stock to Counterparty", "label": "Collaborative Arrangement, Transaction Price, Stock Issued, Premium on Sale of Stock to Counterparty", "terseLabel": "Collaborative arrangement, transaction price, stock issued, premium on sale of stock to counterparty" } } }, "localname": "CollaborativeArrangementTransactionPriceStockIssuedPremiumOnSaleOfStockToCounterparty", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementTransactionPriceUpfrontPayment": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails": { "order": 1.0, "parentTag": "bpmc_CollaborativeArrangementTransactionPrice", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Transaction Price, Upfront Payment", "label": "Collaborative Arrangement, Transaction Price, Upfront Payment", "terseLabel": "Collaborative arrangement, transaction price, upfront payment" } } }, "localname": "CollaborativeArrangementTransactionPriceUpfrontPayment", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Upfront Payment", "label": "Collaborative Arrangement, Upfront Payment", "terseLabel": "Collaborative arrangement, upfront payment" } } }, "localname": "CollaborativeArrangementUpfrontPayment", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CollaborativeArrangementUpfrontPaymentCashPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Upfront Payment, Cash Payment Received", "label": "Collaborative Arrangement, Upfront Payment, Cash Payment Received", "terseLabel": "Collaborative arrangement, upfront payment, cash payment received" } } }, "localname": "CollaborativeArrangementUpfrontPaymentCashPaymentReceived", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_CommonStockIncreaseCapitalSharesReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in aggregate number of common shares reserved for future issuance.", "label": "Common Stock Increase Capital Shares Reserved for Future Issuance", "terseLabel": "Increase of common shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockIncreaseCapitalSharesReservedForFutureIssuance", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "bpmc_ContractWithCustomerAssetAllowanceForCreditLossPriorPeriodIncreaseDecrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time related to prior years.", "label": "Contract With Customer Asset Allowance For Credit Loss Prior Period Increase Decrease", "terseLabel": "Adjustment related to prior periods sales" } } }, "localname": "ContractWithCustomerAssetAllowanceForCreditLossPriorPeriodIncreaseDecrease", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReserveDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_DebtDiscountsAndCapitalizedDebtClosingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Discounts and Capitalized Debt Closing Costs", "label": "Debt Discounts and Capitalized Debt Closing Costs", "negatedLabel": "Debt discounts and capitalized closing costs" } } }, "localname": "DebtDiscountsAndCapitalizedDebtClosingCosts", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_DebtInstrumentCovenantsConsolidatedLiquidityPeriodCommencingFromDateTermLoanFundedToDateDayBeforeNextTermLoansFunded": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Consolidated Liquidity, Period Commencing from Date Term Loan Funded to Date Day before Next Term Loans Funded", "label": "Debt Instrument, Covenants, Consolidated Liquidity, Period Commencing from Date Term Loan Funded to Date Day before Next Term Loans Funded", "terseLabel": "Debt instrument, covenants, consolidated liquidity, period commencing from date term loan funded to date day before next term loans funded" } } }, "localname": "DebtInstrumentCovenantsConsolidatedLiquidityPeriodCommencingFromDateTermLoanFundedToDateDayBeforeNextTermLoansFunded", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_DebtInstrumentCovenantsConsolidatedLiquidityPeriodCommencingFromDateTermLoanFundedToDateDayBeforeNextTermLoansFundedEachDayThereafter": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenants, Consolidated Liquidity, Period Commencing from Date Term Loan Funded to Date Day before Next Term Loans Funded, Each Day Thereafter", "label": "Debt Instrument, Covenants, Consolidated Liquidity, Period Commencing from Date Term Loan Funded to Date Day before Next Term Loans Funded, Each Day Thereafter", "terseLabel": "Debt instrument, covenants, consolidated liquidity, period commencing from date term loan funded to date day before next term loans funded, each day thereafter" } } }, "localname": "DebtInstrumentCovenantsConsolidatedLiquidityPeriodCommencingFromDateTermLoanFundedToDateDayBeforeNextTermLoansFundedEachDayThereafter", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_DebtInstrumentFaceAmountPotentialAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Face Amount, Potential Amount", "label": "Debt Instrument, Face Amount, Potential Amount", "terseLabel": "Debt instrument, face amount, potential amount" } } }, "localname": "DebtInstrumentFaceAmountPotentialAmount", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_DebtInstrumentTranchesNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Tranches, Number", "label": "Debt Instrument, Tranches, Number", "terseLabel": "Debt instrument, tranches, number" } } }, "localname": "DebtInstrumentTranchesNumber", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "integerItemType" }, "bpmc_DebtInstrumentTransactionsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Transactions, Number", "label": "Debt Instrument, Transactions, Number", "terseLabel": "Debt instrument, transactions, number" } } }, "localname": "DebtInstrumentTransactionsNumber", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "integerItemType" }, "bpmc_DebtInstrumentVariableRateFloor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Variable Rate Floor", "label": "Debt Instrument, Variable Rate Floor", "terseLabel": "Debt instrument, variable rate floor" } } }, "localname": "DebtInstrumentVariableRateFloor", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "bpmc_DebtSecuritiesAvailableForSaleCreditRelatedImpairmentsCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, Credit-related Impairments, Charges", "label": "Debt Securities, Available-for-sale, Credit-related Impairments, Charges", "terseLabel": "Marketable debt securities, charges for credit-related impairments" } } }, "localname": "DebtSecuritiesAvailableForSaleCreditRelatedImpairmentsCharges", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesImpairmentDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_DebtSecuritiesAvailableForSaleNumberOfPositions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Number of Positions", "terseLabel": "Securities with remaining maturities greater than one year" } } }, "localname": "DebtSecuritiesAvailableForSaleNumberOfPositions", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesRemainingMaturitiesDetails" ], "xbrltype": "integerItemType" }, "bpmc_EquitySecuritiesWithoutReadilyDeterminableFairValueLicenseAgreementSharesReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Securities without Readily Determinable Fair Value, License Agreement, Shares Received", "label": "Equity Securities without Readily Determinable Fair Value, License Agreement, Shares Received", "terseLabel": "Equity investment, license agreement, shares received (in shares)" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueLicenseAgreementSharesReceived", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "sharesItemType" }, "bpmc_EquitySecuritiesWithoutReadilyDeterminableFairValueTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity Securities without Readily Determinable Fair Value, Transaction Costs", "label": "Equity Securities without Readily Determinable Fair Value, Transaction Costs", "terseLabel": "Equity investment, transaction costs" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueTransactionCosts", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_ExternalResearchDevelopmentAndCommercialContractCosts": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "External Research, Development and Commercial Contract Costs", "label": "External Research, Development and Commercial Contract Costs", "totalLabel": "Accrued expenses" } } }, "localname": "ExternalResearchDevelopmentAndCommercialContractCosts", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_ExternalResearchDevelopmentAndCommercialContractCostsCurrent": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 }, "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "bpmc_ExternalResearchDevelopmentAndCommercialContractCosts", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "External Research, Development and Commercial Contract Costs, Current", "label": "External Research, Development and Commercial Contract Costs, Current", "terseLabel": "External research and development", "verboseLabel": "Accrued expenses, current" } } }, "localname": "ExternalResearchDevelopmentAndCommercialContractCostsCurrent", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_ExternalResearchDevelopmentAndCommercialContractCostsNoncurrent": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "bpmc_ExternalResearchDevelopmentAndCommercialContractCosts", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "External Research, Development and Commercial Contract Costs, Noncurrent", "label": "External Research, Development and Commercial Contract Costs, Noncurrent", "terseLabel": "Accrued expenses, noncurrent" } } }, "localname": "ExternalResearchDevelopmentAndCommercialContractCostsNoncurrent", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_GavretoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "GAVRETO [Member]", "label": "GAVRETO", "terseLabel": "GAVRETO" } } }, "localname": "GavretoMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueDetails" ], "xbrltype": "domainItemType" }, "bpmc_IdrxIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IDRx, Inc [Member]", "label": "IDRx, Inc [Member]", "terseLabel": "IDRx, Inc." } } }, "localname": "IdrxIncMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "domainItemType" }, "bpmc_IncreaseDecreaseInCustomerAssets": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of the amount of customer assets.", "label": "Increase (Decrease) in Customer Assets", "negatedLabel": "Unbilled accounts receivable" } } }, "localname": "IncreaseDecreaseInCustomerAssets", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bpmc_InducementPlan2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inducement Plan, 2020 [Member]", "label": "2020 Inducement Plan" } } }, "localname": "InducementPlan2020Member", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2020InducementPlanDetails" ], "xbrltype": "domainItemType" }, "bpmc_InventoryCurrentAndNoncurrentFinishedGoodsNetOfReserves": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureInventoryCapitalizedDetails": { "order": 2.0, "parentTag": "bpmc_InventoryCurrentAndNoncurrentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory, Current and Noncurrent, Finished Goods, Net of Reserves", "label": "Inventory, Current and Noncurrent, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryCurrentAndNoncurrentFinishedGoodsNetOfReserves", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureInventoryCapitalizedDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_InventoryCurrentAndNoncurrentNet": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureInventoryBalanceSheetClassificationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.blueprintmedicines.com/role/DisclosureInventoryCapitalizedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory, Current and Noncurrent, Net", "label": "Inventory, Current and Noncurrent, Net", "totalLabel": "Total" } } }, "localname": "InventoryCurrentAndNoncurrentNet", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureInventoryBalanceSheetClassificationDetails", "http://www.blueprintmedicines.com/role/DisclosureInventoryCapitalizedDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_InventoryCurrentAndNoncurrentRawMaterialsNetOfReserves": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureInventoryCapitalizedDetails": { "order": 3.0, "parentTag": "bpmc_InventoryCurrentAndNoncurrentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory, Current and Noncurrent, Raw Materials, Net of Reserves", "label": "Inventory, Current and Noncurrent, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryCurrentAndNoncurrentRawMaterialsNetOfReserves", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureInventoryCapitalizedDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_InventoryCurrentAndNoncurrentWorkInProcessNetOfReserves": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureInventoryCapitalizedDetails": { "order": 1.0, "parentTag": "bpmc_InventoryCurrentAndNoncurrentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory, Current and Noncurrent, Work in Process, Net of Reserves", "label": "Inventory, Current and Noncurrent, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryCurrentAndNoncurrentWorkInProcessNetOfReserves", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureInventoryCapitalizedDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_LeaseRightOfUseAssetAmortization": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease, Right-of-Use Asset, Amortization.", "label": "Lease, Right-of-Use Asset, Amortization", "terseLabel": "Non-cash lease expense" } } }, "localname": "LeaseRightOfUseAssetAmortization", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bpmc_LicenseMilestoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Milestone [Member]", "label": "License milestone revenue" } } }, "localname": "LicenseMilestoneMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails" ], "xbrltype": "domainItemType" }, "bpmc_LicenseRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License, Related Party [Member]", "label": "License, Related Party [Member]", "terseLabel": "License revenue - related party" } } }, "localname": "LicenseRelatedPartyMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "bpmc_ManufacturingAgreementOctober2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing Agreement, October 2020 [Member]", "label": "Manufacturing Agreement, October 2020" } } }, "localname": "ManufacturingAgreementOctober2020Member", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "xbrltype": "domainItemType" }, "bpmc_NetProceedsFromStockOptionExercisesAndEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net Proceeds from Stock Option Exercises and Employee Stock Purchase Plan", "label": "Net Proceeds from Stock Option Exercises and Employee Stock Purchase Plan", "terseLabel": "Net proceeds from stock option exercises and employee stock purchase plan" } } }, "localname": "NetProceedsFromStockOptionExercisesAndEmployeeStockPurchasePlan", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bpmc_NoncashCustomerConsideration": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash customer consideration", "label": "Noncash customer consideration", "negatedLabel": "Non-cash customer consideration" } } }, "localname": "NoncashCustomerConsideration", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bpmc_NoncashInterestExpense": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Interest Expense", "label": "Noncash Interest Expense", "terseLabel": "Non-cash interest expense" } } }, "localname": "NoncashInterestExpense", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bpmc_ProteovantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Proteovant [Member]", "label": "Proteovant [Member]", "terseLabel": "Proteovant" } } }, "localname": "ProteovantMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "bpmc_PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesAmountMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Amount, Maximum", "label": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Amount, Maximum", "terseLabel": "Purchase and sale agreement, royalties, future royalty payments, annual worldwide net product sales, amount, maximum" } } }, "localname": "PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesAmountMaximum", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesCumulativeCapOfUpfrontInvestedCapitalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Cumulative Cap of Upfront Invested Capital, Amount", "label": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Cumulative Cap of Upfront Invested Capital, Amount", "terseLabel": "Purchase and sale agreement, royalties, future royalty payments, annual worldwide net product sales, cumulative cap of upfront invested capital, amount" } } }, "localname": "PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesCumulativeCapOfUpfrontInvestedCapitalAmount", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesCumulativeCapOfUpfrontInvestedCapitalRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Cumulative Cap of Upfront Invested Capital, Ratio", "label": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Cumulative Cap of Upfront Invested Capital, Ratio", "terseLabel": "Purchase and sale agreement, royalties, future royalty payments, annual worldwide net product sales, cumulative cap of upfront invested capital, ratio" } } }, "localname": "PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesCumulativeCapOfUpfrontInvestedCapitalRatio", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails" ], "xbrltype": "pureItemType" }, "bpmc_PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesCumulativeCapOfUpfrontInvestedCapitalRevenueTargetsNotAchievedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Cumulative Cap of Upfront Invested Capital, Revenue Targets Not Achieved, Amount", "label": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Cumulative Cap of Upfront Invested Capital, Revenue Targets Not Achieved, Amount", "terseLabel": "Purchase and sale agreement, royalties, future royalty payments, annual worldwide net product sales, cumulative cap of upfront invested capital, revenue targets not achieved, amount" } } }, "localname": "PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesCumulativeCapOfUpfrontInvestedCapitalRevenueTargetsNotAchievedAmount", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesCumulativeCapOfUpfrontInvestedCapitalRevenueTargetsNotAchievedPercentageIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Cumulative Cap of Upfront Invested Capital, Revenue Targets Not Achieved, Percentage Increase", "label": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Cumulative Cap of Upfront Invested Capital, Revenue Targets Not Achieved, Percentage Increase", "terseLabel": "Purchase and sale agreement, royalties, future royalty payments, annual worldwide net product sales, cumulative cap of upfront invested capital, revenue targets not achieved, percentage increase (as a percent)" } } }, "localname": "PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesCumulativeCapOfUpfrontInvestedCapitalRevenueTargetsNotAchievedPercentageIncrease", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails" ], "xbrltype": "percentItemType" }, "bpmc_PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesCumulativeCapOfUpfrontInvestedCapitalRevenueTargetsNotAchievedRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Cumulative Cap of Upfront Invested Capital, Revenue Targets Not Achieved, Ratio", "label": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Cumulative Cap of Upfront Invested Capital, Revenue Targets Not Achieved, Ratio", "terseLabel": "Purchase and sale agreement, royalties, future royalty payments, annual worldwide net product sales, cumulative cap of upfront invested capital, revenue targets not achieved, ratio" } } }, "localname": "PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesCumulativeCapOfUpfrontInvestedCapitalRevenueTargetsNotAchievedRatio", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails" ], "xbrltype": "pureItemType" }, "bpmc_PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesPercentageRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Percentage Rate", "label": "Purchase and Sale Agreement, Royalties, Future Royalty Payments, Annual Worldwide Net Product Sales, Percentage Rate", "terseLabel": "Purchase and sale agreement, royalties, future royalty payments, annual worldwide net product sales, percentage rate (as a percent)" } } }, "localname": "PurchaseAndSaleAgreementRoyaltiesFutureRoyaltyPaymentsAnnualWorldwideNetProductSalesPercentageRate", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails" ], "xbrltype": "percentItemType" }, "bpmc_RevenueFromContractWithCustomerIncludingAssessedTaxCumulativeRevenueCatchUp": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from Contract with Customer, Including Assessed Tax, Cumulative Revenue Catch-up", "label": "Revenue from Contract with Customer, Including Assessed Tax, Cumulative Revenue Catch-up", "terseLabel": "Cumulative revenue catch-up" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTaxCumulativeRevenueCatchUp", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_RevenuePerformanceObligationPerformanceObligationsNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Performance Obligation, Performance Obligations, Number", "label": "Revenue, Performance Obligation, Performance Obligations, Number", "terseLabel": "Revenue, performance obligation, performance obligations, number" } } }, "localname": "RevenuePerformanceObligationPerformanceObligationsNumber", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails" ], "xbrltype": "integerItemType" }, "bpmc_RocheCollaborationAndLicenseImmunotherapyAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Roche, Collaboration and License (Immunotherapy) Agreement [Member]", "label": "Roche, Collaboration and License (Immunotherapy) Agreement" } } }, "localname": "RocheCollaborationAndLicenseImmunotherapyAgreementMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "bpmc_RocheCollaborationAndLicenseImmunotherapyAgreementPhaseIClinicalTrialsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Roche, Collaboration and License (Immunotherapy) Agreement, Phase I Clinical Trials [Member]", "label": "Roche, Collaboration and License (Immunotherapy) Agreement, Phase I Clinical Trials [Member]", "terseLabel": "Roche, Collaboration and License (Immunotherapy) Agreement, Phase I Clinical Trials" } } }, "localname": "RocheCollaborationAndLicenseImmunotherapyAgreementPhaseIClinicalTrialsMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "bpmc_RocheCollaborationPralsetnibAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Roche, Collaboration (Pralsetnib) Agreement [Member]", "label": "Roche, Collaboration (Pralsetnib) Agreement" } } }, "localname": "RocheCollaborationPralsetnibAgreementMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsCollaborationLossSharingDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "bpmc_RocheMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Roche [Member]", "label": "Roche" } } }, "localname": "RocheMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsCollaborationLossSharingDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "bpmc_RoyaltyPharmaRoyaltyPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Pharma, Royalty Purchase Agreement [Member]", "label": "Royalty Pharma, Royalty Purchase Agreement [Member]", "terseLabel": "Royalty Pharma, Royalty Purchase Agreement" } } }, "localname": "RoyaltyPharmaRoyaltyPurchaseAgreementMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "bpmc_RoyaltyPurchaseAgreementMilestonePaymentsAchievementOfSpecifiedNetSalesMilestonesMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Royalty Purchase Agreement, Milestone Payments, Achievement of Specified Net Sales Milestones, Maximum", "label": "Royalty Purchase Agreement, Milestone Payments, Achievement of Specified Net Sales Milestones, Maximum", "terseLabel": "Royalty Purchase Agreement, milestone payments, achievement of specified net sales milestones, maximum" } } }, "localname": "RoyaltyPurchaseAgreementMilestonePaymentsAchievementOfSpecifiedNetSalesMilestonesMaximum", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_SaleOfFutureRoyaltiesAndRevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Future Royalties and Revenues [Member]", "label": "Sale of Future Royalties and Revenues [Member]", "terseLabel": "Sale of Future Royalties and Revenues" } } }, "localname": "SaleOfFutureRoyaltiesAndRevenuesMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "bpmc_ScheduleOfAmountsRecognizedAsReductionsToExpensesCollaborativeArrangementTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amounts recognized as reductions to expenses in collaborative arrangements.", "label": "Schedule of Amounts Recognized as Reductions to Expenses, Collaborative Arrangement [Table Text Block]", "terseLabel": "Schedule of amounts recognized as reductions to expenses" } } }, "localname": "ScheduleOfAmountsRecognizedAsReductionsToExpensesCollaborativeArrangementTableTextBlock", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables" ], "xbrltype": "textBlockItemType" }, "bpmc_ScheduleOfCollaborationLossSharingTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of collaboration loss sharing.", "label": "Schedule of Collaboration Loss Sharing [Table Text Block]", "terseLabel": "Schedule of collaboration loss sharing" } } }, "localname": "ScheduleOfCollaborationLossSharingTableTextBlock", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables" ], "xbrltype": "textBlockItemType" }, "bpmc_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of current and noncurrent inventory.", "label": "Schedule of Inventory, Current and Noncurrent [Table Text Block]", "terseLabel": "Schedule of capitalized inventory" } } }, "localname": "ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureInventoryTables" ], "xbrltype": "textBlockItemType" }, "bpmc_ScheduleOfManufacturingServicesRelatedToAgreementActivitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of manufacturing services related to the global development activities.", "label": "Schedule of Manufacturing Services Related to Agreement Activities [Table Text Block]", "terseLabel": "Summary of manufacturing and research and development services related to the global development activities" } } }, "localname": "ScheduleOfManufacturingServicesRelatedToAgreementActivitiesTableTextBlock", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables" ], "xbrltype": "textBlockItemType" }, "bpmc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of additional shares authorized for issuance under an established share-based compensation plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Additional Shares Authorized", "terseLabel": "Increase in number of shares available for grant (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAdditionalSharesAuthorized", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2015StockOptionAndIncentivePlanDetails" ], "xbrltype": "percentItemType" }, "bpmc_SignificantAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of significant accounting policies.", "label": "Significant Accounting Policy [Policy Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPolicyPolicyTextBlock", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bpmc_SixthStreetPartnersFinancingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Partners, Financing Agreement [Member]", "label": "Sixth Street Partners, Financing Agreement [Member]", "terseLabel": "Sixth Street Partners, Financing Agreement" } } }, "localname": "SixthStreetPartnersFinancingAgreementMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables" ], "xbrltype": "domainItemType" }, "bpmc_SixthStreetPartnersFinancingAgreementSeniorSecuredDelayedDrawTermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Partners, Financing Agreement, Senior Secured Delayed Draw Term Loan Facility [Member]", "label": "Sixth Street Partners, Financing Agreement, Senior Secured Delayed Draw Term Loan Facility [Member]", "terseLabel": "Sixth Street Partners, Financing Agreement, Senior Secured Delayed Draw Term Loan Facility" } } }, "localname": "SixthStreetPartnersFinancingAgreementSeniorSecuredDelayedDrawTermLoanFacilityMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "bpmc_SixthStreetPartnersFinancingAgreementSeniorSecuredTermLoanFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Partners, Financing Agreement, Senior Secured Term Loan Facilities [Member]", "label": "Sixth Street Partners, Financing Agreement, Senior Secured Term Loan Facilities [Member]", "terseLabel": "Sixth Street Partners, Financing Agreement, Senior Secured Term Loan Facilities" } } }, "localname": "SixthStreetPartnersFinancingAgreementSeniorSecuredTermLoanFacilitiesMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables" ], "xbrltype": "domainItemType" }, "bpmc_SixthStreetPartnersFinancingAgreementSeniorSecuredTermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Partners, Financing Agreement, Senior Secured Term Loan Facility [Member]", "label": "Sixth Street Partners, Financing Agreement, Senior Secured Term Loan Facility [Member]", "terseLabel": "Sixth Street Partners, Financing Agreement, Senior Secured Term Loan Facility" } } }, "localname": "SixthStreetPartnersFinancingAgreementSeniorSecuredTermLoanFacilityMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables" ], "xbrltype": "domainItemType" }, "bpmc_SixthStreetPartnersFinancingArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Partners, Financing Arrangements [Member]", "label": "Sixth Street Partners, Financing Arrangements [Member]", "terseLabel": "Sixth Street Partners, Financing Arrangements" } } }, "localname": "SixthStreetPartnersFinancingArrangementsMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "bpmc_SixthStreetPartnersFutureRevenuePurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Partners, Future Revenue Purchase Agreement [Member]", "label": "Sixth Street Partners, Future Revenue Purchase Agreement [Member]", "terseLabel": "Sixth Street Partners, Future Revenue Purchase Agreement" } } }, "localname": "SixthStreetPartnersFutureRevenuePurchaseAgreementMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "bpmc_SixthStreetPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sixth Street Partners [Member]", "label": "Sixth Street Partners [Member]", "terseLabel": "Sixth Street Partners" } } }, "localname": "SixthStreetPartnersMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails" ], "xbrltype": "domainItemType" }, "bpmc_StockIssuedDuringPeriodValueNewIssuesPremium": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails": { "order": 2.0, "parentTag": "bpmc_StockIssuedDuringPeriodValueNewIssuesPurchaseConsideration", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, New Issues, Premium", "label": "Stock Issued During Period, Value, New Issues, Premium", "terseLabel": "Share purchase consideration, premium" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesPremium", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_StockIssuedDuringPeriodValueNewIssuesPurchaseConsideration": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, New Issues, Purchase Consideration", "label": "Stock Issued During Period, Value, New Issues, Purchase Consideration", "totalLabel": "Purchase consideration" } } }, "localname": "StockIssuedDuringPeriodValueNewIssuesPurchaseConsideration", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_StockOptionAndIncentivePlan2015Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the stock option and incentive plan approved in 2015.", "label": "2015 Stock Option and Incentive Plan" } } }, "localname": "StockOptionAndIncentivePlan2015Member", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2015StockOptionAndIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "bpmc_TerritorySpecificActivitiesManufacturingAndResearchAndDevelopmentServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Territory-specific Activities, Manufacturing and Research and Development Services [Member]", "label": "Territory-specific Activities, Manufacturing and Research and Development Services [Member]", "terseLabel": "Territory-specific activities, manufacturing and research and development services" } } }, "localname": "TerritorySpecificActivitiesManufacturingAndResearchAndDevelopmentServicesMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails" ], "xbrltype": "domainItemType" }, "bpmc_TerritorySpecificActivitiesManufacturingServicesAndRoyaltyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Territory-specific Activities, Manufacturing Services and Royalty [Member]", "label": "Territory-specific activities, manufacturing services and royalty" } } }, "localname": "TerritorySpecificActivitiesManufacturingServicesAndRoyaltyMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails" ], "xbrltype": "domainItemType" }, "bpmc_TerritorySpecificActivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Territory-specific Activities [Member]", "label": "Territory-specific Activities [Member]", "terseLabel": "Territory-specific activities" } } }, "localname": "TerritorySpecificActivitiesMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails" ], "xbrltype": "domainItemType" }, "bpmc_UnbilledReceivablesIncludingReimbursableCostsCurrent": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unbilled Receivables, Including Reimbursable Costs, Current", "label": "Unbilled Receivables, Including Reimbursable Costs, Current", "terseLabel": "Unbilled accounts receivable" } } }, "localname": "UnbilledReceivablesIncludingReimbursableCostsCurrent", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "bpmc_UnrecordedUnconditionalPurchaseObligationPeriodIncreaseDecrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecorded Unconditional Purchase Obligation, Period Increase (Decrease)", "label": "Unrecorded Unconditional Purchase Obligation, Period Increase (Decrease)", "terseLabel": "Unrecorded unconditional purchase obligation, period increase (decrease)" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationPeriodIncreaseDecrease", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "bpmc_ZaiLabShanghaiCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zai Lab (Shanghai) Co., Ltd. [Member]", "label": "Zai Lab (Shanghai) Co., Ltd.", "terseLabel": "Zai Lab (Shanghai) Co., Ltd." } } }, "localname": "ZaiLabShanghaiCoLtdMember", "nsuri": "http://www.blueprintmedicines.com/20220930", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingParValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.", "label": "Entity Listing, Par Value Per Share" } } }, "localname": "EntityListingParValuePerShare", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "perShareItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r36", "r38", "r91", "r92", "r232", "r255" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsCollaborationLossSharingDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsManufacturingAndResearchAndDevelopmentServicesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails", "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "domainItemType" }, "srt_ManagementMember": { "auth_ref": [ "r150", "r414" ], "lang": { "en-us": { "role": { "label": "Management [Member]" } } }, "localname": "ManagementMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r147", "r208", "r209", "r271", "r274", "r451", "r499", "r500" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesTables", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r147", "r208", "r209", "r271", "r274", "r451", "r499", "r500" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesTables", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r37", "r38", "r91", "r92", "r232", "r255" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsCollaborationLossSharingDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsManufacturingAndResearchAndDevelopmentServicesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails", "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r23", "r418" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable, Net" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesRevenueRelatedReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r151", "r152" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable", "verboseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesRevenueRelatedReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "verboseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r17", "r42", "r43", "r44", "r488", "r505", "r506" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r41", "r44", "r51", "r52", "r53", "r95", "r96", "r97", "r364", "r411", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15", "r418" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r95", "r96", "r97", "r332", "r333", "r334", "r374" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r291", "r336", "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r325" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails": { "order": 2.0, "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense included in total cost and operating expenses", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByClassificationDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossesTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for allowance for credit losses.", "label": "Allowance for Credit Losses [Text Block]", "terseLabel": "Product Revenue Reserves and Allowances" } } }, "localname": "AllowanceForCreditLossesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowances" ], "xbrltype": "textBlockItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsCollaborationLossSharingDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsManufacturingAndResearchAndDevelopmentServicesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r9", "r87", "r136", "r139", "r145", "r173", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r359", "r365", "r386", "r416", "r418", "r467", "r484" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r22", "r87", "r173", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r359", "r365", "r386", "r416", "r418" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r377" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r159" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax", "verboseLabel": "Unrealized gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r160" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails": { "order": 2.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Abstract]", "terseLabel": "Marketable Securities" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesImpairmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss [Abstract]", "verboseLabel": "Unrealized loss position, aggregate fair value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract]", "terseLabel": "Investments, available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesRemainingMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value", "terseLabel": "Aggregate fair value with remaining maturities greater than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesRemainingMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r155", "r158", "r185", "r471" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails": { "order": 3.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available-for-sale Securities, Debt Securities", "terseLabel": "Marketable securities, available-for-sale", "verboseLabel": "Fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails", "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r157", "r185" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Available-for-sale Securities, Debt Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r7", "r157", "r185" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Available-for-sale Securities, Debt Securities, Noncurrent", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]", "terseLabel": "Marketable securities, available-for-sale:" } } }, "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Realized Gain (Loss) [Abstract]", "verboseLabel": "Realized gains (losses) from maturities of debt securities" } } }, "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesRealizedGainsLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions [Abstract]", "terseLabel": "Unrealized loss position, number of positions" } } }, "localname": "AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationUnrecognizedCompensationCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesRevenueRelatedReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesRevenueRelatedReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r82", "r83", "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Property and equipment purchases unpaid at period end" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r6", "r80" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r74", "r80", "r85" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash shown in condensed consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r74", "r387" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Leases" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeasesCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in Contract with Customer, Asset and Liability [Abstract]" } } }, "localname": "ChangeInContractWithCustomerAssetAndLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in Contract with Customer, Liability [Abstract]", "terseLabel": "Change in Contract with Customer, Liability" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r353", "r354", "r356" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration and License Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsCollaborationLossSharingDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsManufacturingAndResearchAndDevelopmentServicesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaboration Agreements" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsCollaborationLossSharingDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsManufacturingAndResearchAndDevelopmentServicesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r33", "r472", "r492" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 15)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r198", "r200", "r202", "r210", "r510" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Number of common shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r95", "r96", "r374" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Common Stock Disclosures" } } }, "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14", "r418" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.001 par value; 120,000,000 shares authorized; 59,808,492 and 59,141,086 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Income Taxes" } } }, "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r47", "r49", "r50", "r56", "r475", "r495" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": { "auth_ref": [ "r175", "r177", "r180", "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Allowance for Credit Loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "verboseLabel": "Revenue-related reserves" } } }, "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReserveDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesRevenueRelatedReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Classified [Abstract]", "terseLabel": "Contract Assets" } } }, "localname": "ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRecovery": { "auth_ref": [ "r179" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, from recovery.", "label": "Contract with Customer, Asset, Allowance for Credit Loss, Recovery", "negatedLabel": "Credits and payments made" } } }, "localname": "ContractWithCustomerAssetAllowanceForCreditLossRecovery", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReserveDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Product revenue allowance and reserve" } } }, "localname": "ContractWithCustomerAssetAllowanceForCreditLossRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReserveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]" } } }, "localname": "ContractWithCustomerAssetAndLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Summary of contract assets and/or contract liabilities", "verboseLabel": "Schedule of product revenue allowance and reserve categories" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetCreditLossExpense": { "auth_ref": [ "r178", "r266", "r270" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Credit Loss Expense (Reversal)", "terseLabel": "Provision related to sales in the current period" } } }, "localname": "ContractWithCustomerAssetCreditLossExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueAllowanceAndReserveDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]", "terseLabel": "Revenue-related reserves" } } }, "localname": "ContractWithCustomerAssetNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesRevenueRelatedReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r263", "r264", "r272" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "totalLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability [Abstract]", "terseLabel": "Contract Liabilities" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r263", "r264", "r272" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 }, "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Current portion of deferred revenue", "verboseLabel": "Contract liabilities, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r263", "r264", "r272" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 }, "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "verboseLabel": "Contract liabilities, noncurrent" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r273" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Amounts included in the contact liability at the beginning of the period" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r60", "r451" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r59" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total cost and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r10", "r11", "r12", "r86", "r93", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r249", "r250", "r251", "r252", "r397", "r468", "r469", "r483" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r228", "r249", "r250", "r395", "r397", "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r28", "r248", "r395", "r397" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, interest rate, effective percentage (as a percent)" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentageAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage [Abstract]", "terseLabel": "Effective Interest Rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentageAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentIssuanceDate1": { "auth_ref": [ "r30", "r231" ], "lang": { "en-us": { "role": { "documentation": "Date the debt instrument was issued, in YYYY-MM-DD format.", "label": "Debt Instrument, Issuance Date", "terseLabel": "Debt instrument, issuance date" } } }, "localname": "DebtInstrumentIssuanceDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Financing Arrangements" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r29", "r231", "r381" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt instrument, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r31", "r86", "r93", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r249", "r250", "r251", "r252", "r397" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r31", "r86", "r93", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r249", "r250", "r251", "r252", "r258", "r259", "r260", "r261", "r394", "r395", "r397", "r398", "r482" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRoyaltyAndSalesInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r235", "r246", "r249", "r250", "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt discounts and transaction costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Instruments [Abstract]", "terseLabel": "Debt Financing" } } }, "localname": "DebtInstrumentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsAdditionalInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Liabilities related to the sale of future royalties and revenues" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss": { "auth_ref": [ "r161" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, after Allowance for Credit Loss", "totalLabel": "Amortized cost" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r166", "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Unrealized loss position for more than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions", "terseLabel": "Number of held securities in an unrealized loss position for 12 months or longer" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r167" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)", "terseLabel": "Realized gains (losses) from maturities of debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesRealizedGainsLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Schedule of marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r164", "r186" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss", "terseLabel": "Unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r165", "r187" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Number of held securities in an unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesUnrealizedLossPositionDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Transaction costs, gross" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r78", "r134" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesRevenueRelatedReservesDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesTables" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r271", "r274", "r275", "r276", "r277", "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesRevenueRelatedReservesDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesTables" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of revenue recognized" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r293", "r294", "r327", "r328", "r330", "r338" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Text Block [Abstract]", "terseLabel": "Disclosure Text Block" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureAccruedExpenses", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreements", "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingencies", "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstruments", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangements", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxes", "http://www.blueprintmedicines.com/role/DisclosureInventory", "http://www.blueprintmedicines.com/role/DisclosureLeases", "http://www.blueprintmedicines.com/role/DisclosureMarketableSecurities", "http://www.blueprintmedicines.com/role/DisclosureNatureOfBusiness", "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShare", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowances", "http://www.blueprintmedicines.com/role/DisclosureRestrictedCash", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation", "http://www.blueprintmedicines.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r57", "r100", "r101", "r102", "r103", "r104", "r109", "r111", "r113", "r114", "r115", "r119", "r120", "r375", "r376", "r476", "r496" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss) per share - basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r57", "r100", "r101", "r102", "r103", "r104", "r111", "r113", "r114", "r115", "r119", "r120", "r375", "r376", "r476", "r496" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss) per share - diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r116", "r117", "r118", "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]", "terseLabel": "Total stock based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByClassificationDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseGeneralInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r326" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails": { "order": 1.0, "parentTag": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "negatedLabel": "Capitalized stock-based compensation costs" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByClassificationDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r329" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Total unrecognized compensation cost related to non-vested stock awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationUnrecognizedCompensationCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]", "terseLabel": "Stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationUnrecognizedCompensationCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period over which unrecognized compensation cost will be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationUnrecognizedCompensationCostsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r329" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Total unrecognized compensation cost related to non-vested stock option awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationUnrecognizedCompensationCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r51", "r52", "r53", "r95", "r96", "r97", "r99", "r105", "r107", "r122", "r174", "r257", "r262", "r332", "r333", "r334", "r344", "r345", "r374", "r388", "r389", "r390", "r391", "r392", "r393", "r411", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]", "terseLabel": "Equity Investment" } } }, "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r169" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investment" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.", "label": "Equity Securities without Readily Determinable Fair Value [Policy Text Block]", "terseLabel": "Equity Investment" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r377", "r378", "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r377", "r378", "r379", "r383", "r384" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of financial instruments measured at fair value" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r237", "r249", "r250", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r378", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r377", "r378", "r380", "r381", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel12And3Member": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).", "label": "Fair Value, Inputs, Level 1, 2 and 3 [Member]" } } }, "localname": "FairValueInputsLevel12And3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r237", "r281", "r282", "r287", "r289", "r378", "r422" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Active Markets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r237", "r249", "r250", "r281", "r282", "r287", "r289", "r378", "r423" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r237", "r249", "r250", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r422", "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r382", "r385" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Net Asset (Liability) [Abstract]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueNetAssetLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r162", "r163", "r169", "r170", "r171", "r176", "r181", "r182", "r183", "r184", "r188", "r190", "r191", "r192", "r245", "r256", "r373", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails", "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GuaranteeObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written or oral contract that obligates the guarantor to either pay cash or perform services if another party fails to perform specified actions or achieve specified results.", "label": "Guarantee Obligations [Member]" } } }, "localname": "GuaranteeObligationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesIndemnificationAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r54", "r136", "r138", "r141", "r144", "r146", "r464", "r473", "r478", "r497" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r196", "r197" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByClassificationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r88", "r341", "r342", "r343", "r346", "r348", "r350", "r351", "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r89", "r106", "r107", "r135", "r340", "r347", "r349", "r498" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesIncomeTaxExpenseBenefitDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for taxes, net" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r77" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r77" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r77" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r77", "r449" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r77" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r77", "r404" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r77" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r77" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndemnificationGuaranteeMember": { "auth_ref": [ "r211", "r214" ], "lang": { "en-us": { "role": { "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.", "label": "Indemnification Agreement [Member]", "terseLabel": "Indemnification Agreement" } } }, "localname": "IndemnificationGuaranteeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesIndemnificationAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r64", "r243", "r251", "r252" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Interest expense recognized" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r477" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest income (expense), net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "negatedLabel": "Interest payments" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r72", "r75", "r81" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureInventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r21", "r418" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureInventoryBalanceSheetClassificationDetails": { "order": 1.0, "parentTag": "bpmc_InventoryCurrentAndNoncurrentNet", "weight": 1.0 }, "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureInventoryBalanceSheetClassificationDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventory" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureInventoryWriteDownDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r8" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureInventoryBalanceSheetClassificationDetails": { "order": 2.0, "parentTag": "bpmc_InventoryCurrentAndNoncurrentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureInventoryBalanceSheetClassificationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Noncurrent [Abstract]", "terseLabel": "Inventory" } } }, "localname": "InventoryNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureInventoryBalanceSheetClassificationDetails", "http://www.blueprintmedicines.com/role/DisclosureInventoryCapitalizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r193" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory write-down" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureInventoryWriteDownDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAndCash": { "auth_ref": [ "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.", "label": "Investments and Cash", "terseLabel": "Cash, cash equivalents and marketable securities" } } }, "localname": "InvestmentsAndCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAndCashAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments and Cash [Abstract]", "terseLabel": "Cash, cash equivalents and marketable securities" } } }, "localname": "InvestmentsAndCashAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNatureOfBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r168", "r465", "r480", "r507", "r524" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r408", "r409" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Net lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating leases cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of lease expenses and cash flow and weighted average information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee Disclosure [Abstract]", "terseLabel": "Leases" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25", "r87", "r140", "r173", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r360", "r365", "r366", "r386", "r416", "r417" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r20", "r87", "r173", "r386", "r418", "r470", "r490" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r27", "r87", "r173", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r360", "r365", "r366", "r386", "r416", "r417", "r418" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License revenue" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_LoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation.", "label": "Loans Payable [Member]", "terseLabel": "Loans Payable" } } }, "localname": "LoansPayableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r12", "r236", "r247", "r249", "r250", "r469", "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "periodEndLabel": "Carrying value, ending balance", "periodStartLabel": "Carrying value, beginning balance", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Unclassified [Abstract]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Debt and Lease Obligation, Including Current Maturities [Abstract]" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "Financing Arrangements" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r31", "r216" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsLongTermDebtDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r203", "r205", "r206", "r207", "r208", "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesIndemnificationAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesIndemnificationAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r203", "r205", "r206", "r207", "r208", "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesIndemnificationAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r203", "r204" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Loss contingency accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesIndemnificationAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Disclosures [Abstract]", "terseLabel": "Indemnification Agreements" } } }, "localname": "LossContingencyAccrualDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesIndemnificationAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r203", "r205", "r206", "r207", "r208", "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesIndemnificationAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r123", "r131" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNatureOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r74" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r74", "r76", "r79" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r45", "r48", "r53", "r55", "r79", "r87", "r98", "r100", "r101", "r102", "r103", "r106", "r107", "r112", "r136", "r138", "r141", "r144", "r146", "r173", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r376", "r386", "r474", "r494" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Cost and operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r402", "r409" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r400" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r400" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r401", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating lease liabilities", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeasesCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r399" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r407", "r409" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r406", "r409" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term in years" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeasesWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r94", "r108", "r131", "r369" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies and Recent Accounting Pronouncements" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r8" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r39" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r46", "r49", "r357", "r358", "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r40", "r42" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "verboseLabel": "Unrealized losses on available-for-sale investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtCurrent": { "auth_ref": [ "r10", "r11" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.", "label": "Other Long-Term Debt, Current", "terseLabel": "Current portion of liabilities related to the sale of future royalties and revenues" } } }, "localname": "OtherLongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtNoncurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.", "label": "Other Long-Term Debt, Noncurrent", "terseLabel": "Liabilities related to the sale of future royalties and revenues, net of current portion" } } }, "localname": "OtherLongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r67", "r70" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r65", "r68", "r156" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Available-for-sale Securities, Debt", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r69" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2015StockOptionAndIncentivePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2020InducementPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2015StockOptionAndIncentivePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2020InducementPlanDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Policy Text Block [Abstract]", "terseLabel": "Policy Text Blocks" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Preferred Stock Disclosures" } } }, "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13", "r254" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13", "r254" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValueOutstanding": { "auth_ref": [ "r13" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.", "label": "Preferred Stock, Value, Outstanding", "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Gross proceeds", "verboseLabel": "Sale of future royalties / borrowings" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Long-Term Debt [Abstract]", "terseLabel": "Gross Proceeds" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesFinancingArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r65", "r66", "r156" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities", "terseLabel": "Maturities of investments", "verboseLabel": "Proceeds from the maturities of debt securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesProceedsFromMaturitiesDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from other long-term debt.", "label": "Proceeds from (Repayments of) Other Long-Term Debt", "terseLabel": "Net proceeds from the sale of future royalties and revenues" } } }, "localname": "ProceedsFromRepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfSecuredDebt": { "auth_ref": [], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt wholly or partially secured by collateral. Excludes tax exempt secured debt.", "label": "Proceeds from (Repayments of) Secured Debt", "terseLabel": "Net proceeds from term loan facility" } } }, "localname": "ProceedsFromRepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale [Abstract]", "terseLabel": "Proceeds from the maturities of debt securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesProceedsFromMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product revenue, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesTables", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r45", "r48", "r53", "r73", "r87", "r98", "r106", "r107", "r136", "r138", "r141", "r144", "r146", "r173", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r357", "r361", "r362", "r367", "r368", "r376", "r386", "r478" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r195", "r418", "r481", "r491" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r288", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r288", "r412", "r415", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r339", "r450", "r511" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.", "label": "Restricted Assets Disclosure [Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureRestrictedCash" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r6", "r85", "r466", "r487" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Cash [Abstract]", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureRestrictedCashDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents [Abstract]" } } }, "localname": "RestrictedCashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r8", "r85", "r508" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationUnrecognizedCompensationCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r262", "r418", "r489", "r504", "r506" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r95", "r96", "r97", "r99", "r105", "r107", "r174", "r332", "r333", "r334", "r344", "r345", "r374", "r501", "r503" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r132", "r133", "r137", "r142", "r143", "r147", "r148", "r149", "r269", "r271", "r451" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Performance Obligations" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues", "verboseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesProductRevenueDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r405", "r409" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Lease liabilities arising from obtaining right-of-use assets, operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeasesCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "terseLabel": "Royalty" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of common stock equivalents excluded from calculation of diluted net loss per share applicable to common stockholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsCollaborationLossSharingDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsManufacturingAndResearchAndDevelopmentServicesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r31", "r93", "r249", "r251", "r258", "r259", "r260", "r261", "r394", "r395", "r398", "r482" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of activity within the liability account" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r324", "r335" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByClassificationDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Summary of stock-based compensation expense, allocation by type of awards and recognition in statements of operations" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of restricted stock units activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r290", "r292", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2015StockOptionAndIncentivePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2020InducementPlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationUnrecognizedCompensationCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r297", "r313", "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r10", "r468", "r485" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt, Current", "terseLabel": "Current portion of term loan" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsRollForwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecuredLongTermDebt": { "auth_ref": [ "r31" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.", "label": "Secured Long-Term Debt, Noncurrent", "terseLabel": "Term loan, net of current portion" } } }, "localname": "SecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r61" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByClassificationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r77" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2015StockOptionAndIncentivePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2020InducementPlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested at end of period (in shares)", "periodStartLabel": "Unvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested at end of period (in dollars per share)", "periodStartLabel": "Unvested at beginning or period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2015StockOptionAndIncentivePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2020InducementPlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationUnrecognizedCompensationCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Increase in number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2015StockOptionAndIncentivePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2020InducementPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Initial shares of common stock authorized for issuance of stock awards (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2015StockOptionAndIncentivePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2020InducementPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2015StockOptionAndIncentivePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensation2020InducementPlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Additional disclosures" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period", "negatedLabel": "Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "periodStartLabel": "Outstanding at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Shares - Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price - Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsActivityDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationUnrecognizedCompensationCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any other type of change in shares reserved for issuance.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Other Share Increase (Decrease) in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOtherShareIncreaseDecreaseInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r324" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount", "totalLabel": "Subtotal" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r35", "r51", "r52", "r53", "r95", "r96", "r97", "r99", "r105", "r107", "r122", "r174", "r257", "r262", "r332", "r333", "r334", "r344", "r345", "r374", "r388", "r389", "r390", "r391", "r392", "r393", "r411", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r95", "r96", "r97", "r122", "r451" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r13", "r14", "r257", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "verboseLabel": "Purchase of common stock under ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r14", "r257", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued (in shares)", "verboseLabel": "Issuance of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r13", "r14", "r257", "r262" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock under stock plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r14", "r257", "r262", "r303" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationStockOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r13", "r14", "r257", "r262" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "verboseLabel": "Purchase of common stock under ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r257", "r262" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails": { "order": 1.0, "parentTag": "bpmc_StockIssuedDuringPeriodValueNewIssuesPurchaseConsideration", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r13", "r14", "r262", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Issuance of common stock under stock plan" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r18", "r19", "r87", "r153", "r173", "r386", "r418" ], "calculation": { "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r403", "r409" ], "calculation": { "http://www.blueprintmedicines.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "negatedLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureLeasesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "verboseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsSaleOfStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Table Text Block [Abstract]", "terseLabel": "Table Text Blocks" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureAccruedExpensesTables", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTables", "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsTables", "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsTables", "http://www.blueprintmedicines.com/role/DisclosureInventoryTables", "http://www.blueprintmedicines.com/role/DisclosureLeasesTables", "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTables", "http://www.blueprintmedicines.com/role/DisclosureNetLossPerShareTables", "http://www.blueprintmedicines.com/role/DisclosureProductRevenueReservesAndAllowancesTables", "http://www.blueprintmedicines.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r162", "r163", "r169", "r170", "r171", "r245", "r256", "r373", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r517", "r518", "r519", "r520", "r521", "r522", "r523" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails", "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsChangeInContractWithCustomerLiabilityDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsCollaborationLossSharingDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsContractAssetsAndLiabilitiesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsEquityInvestmentDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsGeneralInformationDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsManufacturingAndResearchAndDevelopmentServicesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsPerformanceObligationsDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsReductionInExpensesDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsRevenueRecognizedDetails", "http://www.blueprintmedicines.com/role/DisclosureCollaborationAndLicenseAgreementsTransactionPriceDetails", "http://www.blueprintmedicines.com/role/DisclosureIncomeTaxesEquityInvestmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Government Corporations and Agencies Securities [Member]", "terseLabel": "U.S. government agency securities" } } }, "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails", "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r90", "r281", "r289", "r479" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury obligations" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFairValueOfFinancialInstrumentsDetails", "http://www.blueprintmedicines.com/role/DisclosureMarketableSecuritiesTabularDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unconditional Purchase Obligations (Excluding Capital Stock Redemptions) [Abstract]", "terseLabel": "Manufacturing Agreements" } } }, "localname": "UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Unrecorded Unconditional Purchase Obligation [Line Items]" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationTable": { "auth_ref": [ "r198", "r199", "r201" ], "lang": { "en-us": { "role": { "documentation": "Describes each unrecorded unconditional purchase obligation arrangement to purchase goods and services that extend over multiple periods, any assets pledged to secure payment, and the fixed or determinable amount of payments due in each of the next five years and thereafter.", "label": "Unrecorded Unconditional Purchase Obligation [Table]" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureCommitmentsAndContingenciesPurchaseCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r124", "r125", "r126", "r127", "r128", "r129", "r130" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/DisclosureFinancingArrangementsGeneralInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r110", "r115" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average number of common shares used in net loss per share - diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r109", "r115" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average number of common shares used in net loss per share - basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blueprintmedicines.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "310", "URI": "https://asc.fasb.org/topic&trid=2196771" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907419&loc=d3e10037-110241" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e13051-110250" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r356": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r369": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r410": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r465": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r480": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1,2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r507": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r512": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r513": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r514": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r515": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r516": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r517": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r518": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r519": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r520": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r521": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r522": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r523": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r524": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r525": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" } }, "version": "2.1" }